Mineralys Therapeutics (MLYS) Interest Expenses (2022 - 2025)

Mineralys Therapeutics (MLYS) has 4 years of Interest Expenses data on file, last reported at $146.3 million in Q4 2025.

• For the quarter ending Q4 2025, Interest Expenses rose 83.06% year-over-year to $146.3 million; the trailing twelve-month figure through Dec 2025 stood at $146.3 million (up 83.06% YoY), and the FY2025 full-year result was $146.3 million, up 83.06% from the prior year.
• Interest Expenses advanced to $146.3 million in Q4 2025, from $79.9 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $146.3 million in Q4 2025 to a low of $857000.0 in Q4 2023.
• A 4-year average of $60.7 million and a median of $47.7 million in 2022 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses slumped 94.49% in 2023 and surged 9226.6% in 2024, its largest moves.
• Tracing MLYS's Interest Expenses over 4 years: stood at $15.6 million in 2022, then tumbled by 94.49% to $857000.0 in 2023, then surged by 9226.6% to $79.9 million in 2024, then soared by 83.06% to $146.3 million in 2025.
• Business Quant data shows MLYS's Interest Expenses at $146.3 million in Q4 2025, $79.9 million in Q4 2024, and $857000.0 in Q4 2023.